In a recent study, Askoura et al. described the role of interleukins IL-33, IL-17, and IL-25 in patients with HCV, the progression of the disease from chronicity to HCC, as well as the importance of using them as biomarkers of disease progression (Table 1). The gene discussed is IL33; the disease is hepatocellular carcinoma.